Anton Y. Peleg, MBBS PhD MPH FRACP
Anton Y. Peleg, MBBS PhD MPH FRACP
Alfred Hospital and Monash University
Verified email at
Cited by
Cited by
Acinetobacter baumannii: Emergence of a Successful Pathogen
AY Peleg, H Seifert, DL Paterson
Clinical microbiology reviews 21 (3), 538-582, 2008
Remdesivir for the treatment of Covid-19—preliminary report
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine, 2020
Hospital-acquired infections due to gram-negative bacteria
AY Peleg, DC Hooper
New England Journal of Medicine 362 (19), 1804-1813, 2010
Common infections in diabetes: pathogenesis, management and relationship to glycaemic control
AY Peleg, T Weerarathna, JS McCarthy, TME Davis
Diabetes/metabolism research and reviews 23 (1), 3-13, 2007
Medically important bacterial–fungal interactions
AY Peleg, DA Hogan, E Mylonakis
Nature reviews microbiology 8 (5), 340-349, 2010
Treatment of Acinetobacter Infections
J Fishbain, AY Peleg
Clinical infectious diseases 51 (1), 79-84, 2010
Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study
AY Peleg, S Husain, ZA Qureshi, FP Silveira, M Sarumi, KA Shutt, ...
Clinical Infectious Diseases 44 (10), 1307-1314, 2007
Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a …
PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ...
Jama 320 (10), 984-994, 2018
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
AY Peleg, BA Potoski, R Rea, J Adams, J Sethi, B Capitano, S Husain, ...
Journal of antimicrobial chemotherapy 59 (1), 128-131, 2007
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
AY Peleg, J Adams, DL Paterson
Antimicrobial agents and chemotherapy 51 (6), 2065-2069, 2007
Phenotypic detection of carbapenem-susceptible metallo-β-lactamase-producing gram-negative bacilli in the clinical laboratory
C Franklin, L Liolios, AY Peleg
Journal of clinical microbiology 44 (9), 3139-3144, 2006
Galleria mellonella as a Model System To Study Acinetobacter baumannii Pathogenesis and Therapeutics
AY Peleg, S Jara, D Monga, GM Eliopoulos, RC Moellering Jr, ...
Antimicrobial agents and chemotherapy 53 (6), 2605-2609, 2009
Management of meningitis due to antibiotic-resistant Acinetobacter species
BN Kim, AY Peleg, TP Lodise, J Lipman, J Li, R Nation, DL Paterson
The Lancet infectious diseases 9 (4), 245-255, 2009
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody
AY Peleg, S Husain, EJ Kwak, FP Silveira, M Ndirangu, J Tran, KA Shutt, ...
Clinical Infectious Diseases 44 (2), 204-212, 2007
Dissemination of the Metallo-β-Lactamase Gene blaIMP-4 among Gram-Negative Pathogens in a Clinical Setting in Australia
AY Peleg, C Franklin, JM Bell, DW Spelman
Clinical Infectious Diseases 41 (11), 1549-1556, 2005
Acinetobacter baumannii: evolution of antimicrobial resistance—treatment options
Y Doi, GL Murray, AY Peleg
Seminars in respiratory and critical care medicine 36 (01), 085-098, 2015
Candida albicans Hyphal Formation and Virulence Assessed Using a Caenorhabditis elegans Infection Model
R Pukkila-Worley, AY Peleg, E Tampakakis, E Mylonakis
Eukaryotic cell 8 (11), 1750-1758, 2009
Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus
AY Peleg, S Miyakis, DV Ward, AM Earl, A Rubio, DR Cameron, S Pillai, ...
PloS one 7 (1), e28316, 2012
Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies
I Abbott, GM Cerqueira, S Bhuiyan, AY Peleg
Expert review of anti-infective therapy 11 (4), 395-409, 2013
Insights into Acinetobacter baumannii pathogenicity
GM Cerqueira, AY Peleg
IUBMB life 63 (12), 1055-1060, 2011
The system can't perform the operation now. Try again later.
Articles 1–20